publicações selecionadas
-
artigo de revista
- RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer. Biomolecules. 2019
- Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. Cells. 2019
- Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells. Oncotarget. 2017
- HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. Theranostics. 2017
-
capítulo de livro
-
documento
- Exploring the predictive and therapeutic value of the embryonic T-box transcription factor Brachyury in lung cancer 2021
- Untangling the role of RKIP in NSCLC aggressiveness – an in vitro/vivo and in silico analysis 2021
- Role of RKIP protein in the modulation of lung cancer cell metabolism. 2021
- "Compreender a regulação e sinalização da RKIP em cancro do colo do útero: RKIP/HER loop" 2021
- A proteína RKIP como um novo preditor de resposta a terapias anti-EGFR em cancro do pulmão 2021
- Fator de transcrição embrionário T-box Brachyury como biomarcador de resposta e alvo terapêutico em cancro do pulmão 2021
- RKIP protein as a novel predictor of EGFR targeted therapies in lung cancer 2021
- RKIP protein as a potential prognostic, aggressiveness and therapy response biomarker in HPV-related cancers 2021
- Embryonic T-box transcription factor Brachyury as a predictive biomarker and therapeutic target in lung cancer 2021
- Role of RKIP protein in the modulation of cancer cells metabolism in solid tumors 2019
- RKIP protein as a potential prognostic, aggressiveness and therapy response biomarker in HNSCC 2019
- RKIP protein as a novel predictor of EGFR targeted therapies in lung cancer 2019
- RKIP protein induces HER receptors activation and positively modulate its pharmacological targeting in cervical cancer 2019
- RKIP protein as a novel predictor of EGFR targeted therapies in lung cancer 2018
- RKIP protein induces HER receptors activation and positively modulate its pharmacological targeting in cervical cancer 2018
- The biological role of RKIP in head and neck cancer: an in vivo and in vitro study 2018
- Understanding the cellular metabolic reprogramming associated with bevacizumab therapy in glioblastoma 2017
- Blocking glucose metabolism enhances the effect of HER inhibitors in cervical cancer therapy 2016
- Blocking glucose metabolism enhances the effect of HER inhibitors in cervical cancer therapy. 2016
- HER receptors are important theranostic biomarkers on cervical cancer: blocking glucose metabolism enhances the therapeutic effect of HER inhibitors 2016
-
teses